|Biotech Due Diligence||
I missed a month, so please enjoy a super-sized collection of recent noteworthy papers in the scientific and medical literature. Happy New Year!
How Facebook and Twitter could be the next disruptive force in clinical trials
Heidi Ledford (Nature News)
A Bold New Strategy for Stopping the Rise of Superbugs
Ed Yong (The Atlantic)
Single-molecule magnet controversy highlights transparency problems with U.K. research integrity system
Mark Peplow (C&EN)
The Trouble With Black-6 [Mice]
Daniel Engber (Slate)
At 24, Two Entrepreneurs Took On Cancer. At 32, They’re Worth Hundreds Of Millions
Matthew Herper (Forbes)
Why Doctors Hate Their Computers
Atul Gawande (The New Yorker)
Meet the Carousing, Harmonica-Playing Texan Who Just Won a Nobel Prize for his Cancer Breakthrough
Charles Graeber (Wired)
It's back! Enjoy another round-up of the news items and SEC filings that these biotech and pharmaceutical companies hoped we didn't see...
Apologies for the lag, but as a result I have a long list of intriguing and influential articles teed up. Enjoy the latest collection here.
How a Rundown Square Near Boston Birthed a Biotech Boom and Real Estate Empire
Rebecca Spalding (Bloomberg)
Fear Of The Flood: Post-IPO Lockup Expiry In Biotech
Bruce Booth (LifeSciVC)
No, LaCroix Isn’t Poisoning You Like You’re A Giant Cockroach
Christie Aschwanden (FiveThirtyEight)
Where Do Recent Small Molecule Clinical Candidates Come From?
Dennis Hu (Drug Hunter)
Two sick children and a $1.5 million bill: One family’s race for a gene therapy cure
Antonio Regalado (MIT Technology Review)
Drug Repurposing, Computed
Derek Lowe (In the Pipeline)
Your support is greatly appreciated